Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Johnson and Johnson
McKesson
McKinsey
Express Scripts

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022504

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 022504 describes AXIRON, which is a drug marketed by Eli Lilly And Co and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the AXIRON profile page.

The generic ingredient in AXIRON is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
Summary for 022504
Tradename:AXIRON
Applicant:Eli Lilly And Co
Ingredient:testosterone
Patents:7
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 022504
Paragraph IV (Patent) Challenges for 022504
Tradename Dosage Ingredient NDA Submissiondate
AXIRON SOLUTION, METERED;TRANSDERMAL testosterone 022504 2013-01-29

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION, METERED;TRANSDERMALStrength30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 23, 2010TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Feb 26, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
Patent:  Start TrialPatent Expiration:Sep 27, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
Patent:  Start TrialPatent Expiration:Jul 13, 2023Product Flag?YSubstance Flag?Delist Request?
Patented Use:A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE

Expired US Patents for NDA 022504

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010   Start Trial   Start Trial
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010   Start Trial   Start Trial
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010   Start Trial   Start Trial
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
McKinsey
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.